ClickCease

Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study

Glue, P., Neehoff, S., Sabadel, A., Broughton, L., Le Nedelec, M., Shadli, S., McNaughton, N., & Medlicott, N. J. (2019). Effects of ketamine in patients with treatment-refractory generalized anxiety and social anxiety disorders: Exploratory double-blind psychoactive-controlled replication study. Journal of Psychopharmacology, 34(3), 267–272.   Highlights: ·         The purpose of this study was to replicate our […]

Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression.

Siegel JS, Palanca BJA, Ances BM, Kharasch ED, Schweiger JA, Yingling MD, Snyder AZ, Nicol GE, Lenze EJ, Farber NB. Prolonged ketamine infusion modulates limbic connectivity and induces sustained remission of treatment-resistant depression. Psychopharmacology (Berl). 2021 Apr;238(4):1157-1169. doi: 10.1007/s00213-021-05762-6. Epub 2021 Jan 22. PMID: 33483802; PMCID: PMC7969576.   Highlights: ·         In this open-label, proof-of-principle study, […]

A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression.

Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L. A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry. 2016 Aug 1;173(8):816-26. doi: […]

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.

Abdallah, C.G., Roache, J.D., Gueorguieva, R. et al. Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial. Neuropsychopharmacol. 47, 1574–1581 (2022). Highlights: The standard ketamine dose treated depression significantly more than placebo. Ketamine produced dose-related dissociative and psychotomimetic effects, which […]

Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.

Anand, A et al. (2023).  Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression.  N Engl J Med 2023;388:2315-25. DOI: 10.1056/NEJMoa2302399  Highlights: A total of 55.4% of the patients in the ketamine group and 41.2% of those in the ECT group had a response. Patients with treatment-resistant major depression without psychosis were recruited and assigned in […]

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active-duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.

ketamine vs antidepressant

Highlights: The standard ketamine dose-treated depression significantly more than placebo. Ketamine produced dose-related dissociative and psychotomimetic effects, which returned to baseline within 2 h and were less pronounced with repeated administration. Involved 158 veterans and service members with treatment-resistant PTSD that failed prior antidepressant treatments in the past. Veterans were divided into a placebo group, and […]

Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression.

Chen, M. H., Wu, H. J., Li, C. T., Lin, W. C., Tsai, S. J., Hong, C. J., Tu, P. C., Bai, Y. M., Mao, W. C., & Su, T. P. (2021). Low-dose ketamine infusion in treatment-resistant double depression: Revisiting the adjunctive ketamine study of Taiwanese patients with treatment-resistant depression. Human Psychopharmacology: Clinical and Experimental, […]

Ketamine and the Future of Rapid-Acting Antidepressants.

Lace M. Riggs and Todd D. Gould.  Ketamine and the Future of Rapid-Acting Antidepressants.  Annual Review of Clinical Psychology 2021 17:1, 207-231   Highlights: The therapeutic onset of traditional antidepressants is delayed by several weeks and many depressed patients fail to respond to treatment altogether. In contrast, subanesthetic ketamine can rapidly alleviate symptoms of depression […]